Evaluating the efficacy and safety of topical sirolimus 0.2% cream as adjuvant therapy with pulsed dye laser for the treatment of port wine stain: A randomized, double-blind, placebo-controlled trial
| Autor: | Maryam Daneshpazhooh, Shahriar Haddady Abianeh, Amir Teimourpour, Zahra Hallaji, Soheil Tavakolpour, Hamidreza Mahmoudi, Ali Nili, Mahsa Fallahi, Javad Rahmati, Ali Salehi Farid, Somayeh Niknam |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Erythema medicine.medical_treatment Port-Wine Stain Placebo-controlled study Lasers Dye Dermatology Placebo 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine medicine Adjuvant therapy Humans Adverse effect Sirolimus business.industry Treatment Outcome 030220 oncology & carcinogenesis Topical Sirolimus Laser Therapy medicine.symptom business Adjuvant Immunosuppressive Agents medicine.drug |
| Zdroj: | Journal of cosmetic dermatologyREFERENCES. 20(8) |
| ISSN: | 1473-2165 |
| Popis: | Introduction Port Wine Stain (PWS) is a congenital capillary malformation. Although multiple treatments are required, the gold standard treatment for PWS is Pulsed Dye Laser (PDL). Given its anti-angiogenic effects, sirolimus can be considered as an adjuvant to PDL in PWS. Aim To evaluate the efficacy and safety of topical sirolimus (Rapamycin) 0.2% cream as adjuvant therapy for PDL for PWS. Methods In this randomized double-blind placebo-controlled trial, 15 patients with PWS were enrolled. Each lesion was divided into upper and lower parts, and each part was assigned randomly to receive PDL (4 sessions, 2 months apart) plus sirolimus versus PDL and placebo. The response was evaluated using colorimetry, investigator global assessment (IGA), and patient global assessment (PGA) every two months for eight continuous months. Results According to the colorimetric analysis, medial and lateral sides of the treatment and placebo parts did not differ significantly (both P-value>0.05). However, according to PGA and IGA, there was a significant difference in favor of sirolimus (P-values= 0.041 and 0.039, respectively). Itching and dryness (86.7%), contact dermatitis (20%) were the most common adverse effects in the sirolimus group, while none of them were observed in placebo. Conclusion Although the improvement was significant subjectively, topical sirolimus 0.2% as an adjuvant to PDL does not appear to improve PWS erythema using calorimetric assessment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|